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Abstract
Background: Development of accurate therapeutic approaches to salivary gland neoplasms depends on better
understanding of their molecular pathogenesis. Tumour growth is regulated by the balance between proliferation
and apoptosis. Few studies have investigated apoptosis in salivary tumours relying almost exclusively on
immunohistochemistry or TUNEL assay. Furthermore, there is no information regarding the mRNA expression
profile of apoptotic genes in salivary tumors. Our objective was to investigate the quantitative expression of BCL-2
(anti-apoptotic), BAX and Caspase3 (pro-apoptotic genes) mRNAs in salivary gland neoplasms and examine the
association of these data with tumour size, proliferative activity and p53 staining (parameters associated with a
poor prognosis of salivary tumours patients).
Methods: We investigated the apoptotic profile of salivary neoplasms in twenty fresh samples of benign and
seven samples of malignant salivary neoplasms, using quantitative real time PCR. We further assessed p53 and ki-67
immunopositivity and obtained clinical tumour size data.
Results: We demonstrated that BCL-2 mRNA is overexpressed in salivary neoplasms, leading to an overall anti-
apoptotic profile. We also found an association between the anti-apoptotic index (BCL-2/BAX) with p53
immunoexpression. A higher proliferative activity was found in the malignant tumours. In addition, tumour size
was associated with cell proliferation but not with the transcription of apoptotic genes.
Conclusion: In conclusion, we show an anti-apoptotic gene expression profile in salivary neoplasms in association
with p53 staining, but independent of cell proliferation and tumour size.
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Background
Salivary gland tumours have an annual global incidence
between 0.4 and 13.5 cases per 100 000 individuals [1].
High proliferative activity, presence of residual tumour
and advanced tumour stage were shown to be strong
negative predictors of survival in salivary gland neo-
plasms [2]. Development of targeted therapy calls for a
better understanding of their molecular and cellular
biology [3].
Apoptosis is a highly regulated active process, charac-
terized by cell shrinkage, chromatin condensation and
DNA fragmentation promoted by endonucleases. Induc-
tion of apoptosis is a normal defense against loss of
growth control which follows DNA mutations. Apopto-
sis is frequently deregulated in human cancers, being a
suitable target for anticancer therapy [4].
The B-cell lymphoma (BCL-2) family comprises differ-
ent regulators involved in apoptosis. BCL-2 is an impor-
tant proto-oncogene located at chromosome 18q21 [5].
It was the first gene implicated in the regulation of
apoptosis. Its protein is able to stop programmed cell
death (apoptosis) facilitating cell survival independent of
promoting cell division [6]. BCL-2 is thought to be
involved in resistance to conventional cancer treatment
and its increased expression has been implicated in a
number of cancers [4]. Apparently, many cancers
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tumour initiation and maintenance [7].
BAX (Bcl-2-associated protein X) is the most charac-
teristic death-promoting member of the BCL-2 family.
The translocation of Bax protein from the cytosol to the
mitochondria triggers the activation of the caspases cas-
cade, leading to death [8]. Caspase 3 (CASP3) was first
described in 1995 and once activated, is considered to
be responsible for the actual demolition of the cell dur-
ing apoptosis [9,10].
In salivary neoplasms, apoptosis has been investigated
almost exclusively by means of immunohistochemistry.
Bcl-2 and Bax proteins are expressed in most of the sali-
vary gland neoplasms investigated, but Bcl-2 positivity
was found in a lower percentage of mucoepidermoid
carcinomas [11-15]. In the studies with TUNEL in sali-
vary gland neoplasms, apoptotic activity was inversely
associated with Bcl-2 immunoexpression [11,15]. In sali-
vary gland carcinomas, TUNEL was associated with a
poor prognosis, being correlated with p53 and ki-67
staining [16]. As the transcription of apoptosis related
genes could help to elucidate the pathogenesis of
tumours, we propose to investigate the quantitative
expression of BCL-2 (anti-apoptotic), BAX and Caspase3
(pro-apoptotic genes) using qPCR. As tumour size, high
proliferative activity and p53 staining are associated with
a poor prognosis of salivary tumours patients [2,17], we
tested the association of these parameters with the tran-
scription of the apoptotic/anti-apoptotic genes.
Methods
Samples
Twenty seven salivary gland neoplasms were included in
this study. Fresh tumour samples were obtained from
patients who underwent surgical excision of salivary
gland neoplasms. The study was approved by the local
ethics committee. The diagnoses were reviewed and
confirmed: 17 pleomorphic adenomas, one basal cell
adenoma, one Warthin tumour, one mucinous cystade-
noma, three polymorphous low grade adenocarcinomas,
two low grade mucoepidermoid carcinomas, one ade-
noid cystic carcinoma and one cystadenocarcinoma. Six
samples of normal salivary glands obtained from healthy
volunteers undergoing surgery for non-neoplastic dis-
ease were used as controls.
For each sample, a portion of the lesion was stored in
RNAHolder (BioAgency Biotecnologia, São Paulo, SP,
Brazil) at -80°C, while another portion was fixed in 10%
buffered formalin and paraffin embedded. All the samples
underwent the same fixation and processing procedures.
Quantitative reverse transcriptase PCR (qRT-PCR)
Total RNA was isolated from samples using Tri-Phasis
Reagent (BioAgency, São Paulo, Brazil) and treated with
DNase (Invitrogen Life Technologies, Carlsbad, CA,
USA). cDNA was synthesized with Superscript First-
Strand Synthesis System kit (Invitrogen Life Technolo-
gies, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. Quantitative PCR analyses were
carried out using 1x SYBR Green PCR Master Mix
(Applied Biosystems, Warrington, CHS, UK). BCL-2,
BAX, CASP3 and ACTB primers were designed using
Primer Express software (Applied Biosystems, Foster
City, CA, USA) version 3.0. The primer sequences are
specified in Table 1. Reactions were performed in dupli-
cate and run on a Step One machine (Applied Biosys-
tems, Foster City, CA, USA). The cycling parameters
were 10 min denaturation at 95°C followed by 40 cycles
at 95°C for 15 s and 56°C for 1 min. The cycling was
followed by melting curve analysis to distinguish specifi-
city of the PCR products. BCL-2, BAX and CASP3
expressions were normalized with actin (ACTB) as inter-
nal control. The average threshold cycle (Ct) for two
replicates per sample was used to calculate ΔCt. Relative
quantification of these genes expressions was calculated
with the 2
-ΔΔCt method. Normal salivary gland samples
were used as a calibrator.
Apoptosis tendency was estimated by two indexes:
Anti-apoptotic index 1 (AI-1), calculated by the ratio
between BCL-2/BAX expression and anti-apoptotic
index 2 (AI-2), calculated by the ratio between BCL-2/
CASP3. Samples with AI-1 or AI-2 higher than 1 were
regarded as having higher anti-apoptotic activity than
samples exhibiting an AI lower than 1.
Immunohistochemistry
Paraffin-embedded sections (4 μm) were dewaxed in
xylene, hydrated with graded ethanol and endogenous
peroxidase blocked in 1% hydrogen peroxidase for 15
min. Antigen retrieval was performed with citric acid,
pH 6.0. The primary antibodies used were ki-67 (MIB-1)
and p53 (DO7), both from DAKO (Carpinteria, CA,
USA) and diluted 1:50. Primary antiserum incubation
was performed for 30 min at room temperature and
binding visualized using a polymer-based system (EnVi-
sion, Dako Corporation, Carpinteria, CA, USA) with dia-
minobenzidine (Sigma, St Louis, MO, USA) as
chromogen. For each antibody, positive (squamous cell
carcinoma with known reactivity) and negative controls
in which the primary antibody was omitted were
included. The sections were counterstained with hema-
toxylin, dehydrated and mounted.
The percentage of ki-67 positive nuclei was obtained
by counting nuclear staining in 10 high power fields
(400 × magnification) including the most positive areas.
Neoplasms were divided into two groups with 5% or
more positive nuclei being considered as high prolifera-
tive activity, or fewer than 5% positive nuclei considered
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counted in eight fields (400 × magnification); more than
5% of positive nuclei was considered positive [18].
Statistical Analyses
Mann-Whitney, Fisher Test and Spearman correlation
tests were used when appropriate. P values < 0.05 were
considered statistically significant. These tests were per-
formed with BioEstat software (Belém, PA, Brazil), ver-
sion 4.
Results
BAX, BCL-2 and CASP3 expression
There was no difference between mRNA expression of
BAX, BCL-2 and CASP3 between malignant and benign
salivary gland neoplasm groups. However, positive cor-
relation was found using the Spearman test for all the
following paired groups: BAX/BCL-2 (p =0 . 0 1 0 ) ,BAX/
CASP3 (p =0 . 0 0 8 ) ,BCL-2/CASP3 (p <0 . 0 0 0 1 ) .O v e r a l l ,
78% (21/27) of the salivary neoplasm samples exhibited
overexpression of BCL-2 mRNA compared to the
expression in normal salivary glands, including 15 out of
17 pleomorphic adenomas. The expression of BAX and
CASP3 in the salivary tumours, however, was higher
than normal glands only in 52% (14/27) and 44% (12/
27) samples, respectively.
Anti-apoptotic indexes
Anti-apoptotic index results are displayed in Table 2
and illustrated in Figure 1. Eighty-five percent (n = 23)
of all salivary neoplasms samples showed a higher AI-1
or AI-2, when compared with normal salivary glands
(Figure 1). AI-1 and AI-2 did not show association with
malignancy. p53 immunopositivity was associated with a
statistically significant higher AI-1 (p = 0.004) (Figure
2). AI-2 was not associated with any of the investigated
parameters.
p53 and cell proliferation index
p53 and cell proliferation results are displayed in Table
2. The samples that were p53 positive in the immuno-
histochemistry also showed a high relative quantification
of BCL-2 (p = 0.0003) and CASP3 mRNA (p = 0.0007).
p53 positivity was also associated with high cellular pro-
liferation index (p = 0.002) (Figure 2). In addition, the
samples exhibiting high cellular proliferation index were
associated with high CASP3 transcriptional levels (p =
0.018). High proliferation index was associated with
malignancy (p = 0.001), as well.
Tumour size
Samples were divided into two groups: tumour size ≤ 2
cm and tumour size > 2 cm. Tumour size showed asso-
ciation with a high cellular proliferation index (p =
0.019), despite showing no association with the tran-
scription of BCL-2, BAX or CASP3,o rw i t ht h ea n t i -
apoptotic indexes.
Discussion
Very little is known about the apoptotic index of sali-
vary gland neoplasms. We used two different anti-apop-
totic indexes (AI-1 and AI-2) to calculate the apoptotic
profile of these lesions. The higher these coefficients
are, the more probable an anti-apoptotic profile is
expected. In contrast, an index < 1 indicates an increase
in BAX or CASP3 or a decrease in BCL-2 mRNA tran-
scription, favoring apoptosis. It has been shown that
Bcl-2 protein forms heterodimers with the Bax protein
such that Bcl-2-Bax inhibits apoptosis, whereas Bax-Bax
homodimers favor it [19]. Tumour growth depends on
the balance between proliferation/apoptotic indexes. In
the present paper we demonstrated that most of the
salivary gland neoplasm samples showed a higher AI-1
and AI-2 when compared to normal salivary glands,
suggesting a predominance of anti-apoptotic behavior in
neoplastic cells, which in turn contributes to neoplasia
growth (Figure 1). This study is the first to demonstrate
that salivary gland tumours present an anti-apoptotic
transcriptional signature.
It was reported, using the 3’-end DNA labeling
method (TUNEL), that in salivary gland neoplasms
apoptosis is inversely associated with Bcl-2 expression,
but not related to Bax expression [11]. This result was
strengthened by another publication using TUNEL
method which described an inverse association between
apoptosis and the expression of Bcl-2 in adenoid cystic
carcinomas [15]. However, in mucoepidermoid carcino-
mas such association did not exist [13]. In the present
paper we have shown an increased BCL-2 mRNA tran-
scription in the salivary tumours compared to normal
salivary glands in 78% of the samples. If we consider
only the pleomorphic adenoma samples, BCL-2
Table 1 qRT-PCR primer sequences and amplicon sizes
cDNA Forward primer Reverse primer Product length
BAX 5’GAGCTGCAGAGGATG ATT GC 3’ 5’CAGCTGCCACTCGGAAAA3’ 70 bp
BCL-2 5’AGGCTGGGATGCCTTTGT3’ 5’CAGCCAGGAGAAATCAAACAG3’ 67 bp
CASP3 5’TCATAAAAGCACTGGAATGACATC3’ 5’TTCTGAATGTTTCCCTGAGGTT3’ 74 bp
ACTB 5’TGCCGACAGGATGCAGAAG3’ 5’CTCAGGAGGAGCAATGATCTTGA3’ 77 bp
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of these tumours. This result supports the above men-
tioned paper by Soini and colleagues (1998) [11], which
pointed to a very low apoptotic index (0.01%) in
pleomorphic adenomas. Our results are in agreement
with another study that described Bcl-2 immunopositiv-
ity in 33/35 samples of pleomorphic adenomas investi-
gated [14]. Also, all the pleomorphic adenomas
Table 2 Benign and malignant tumours data regarding diagnosis, tumour size, p53 staining, cell proliferation index
and anti-apoptotic indexes 1 and 2
Sample Diagnosis Tumour size
a p53 immuno-staining Cell proliferation AI-1 (BCL-2/BAX) AI-2 (BCL-2/CASP3)
#1 PLGA 2 + high 2.370 1.132
#2 PA 1 + low 1.887 4.092
#3 PA 1 - low 4.423 2.665
#4 PA 2 + high 3.584 1.177
#5 PLGA 2 + high 3.765 2.689
#6 PA 2 + high 3.461 2.066
#7 PA - - low 3.493 2.613
#8 PA 2 + low 3.274 6.520
#9 ACC 2 + high 7.386 9.161
#10 PLGA 2 + high 2.913 2.692
#11 PA 1 + low 2.922 7.813
#12 PA 1 - low 0.594 2.276
#13 PA 1 - low 0.788 3.355
#14 PA - - low 1.346 3.800
#15 PA 1 - low 0.873 1.316
#16 PA 2 - low 1.237 2.001
#17 MC - - low 1.333 1.198
#18 PA 2 - low 0.548 15.418
#19 CA 2 - high 0.596 0.673
#20 PA - - low 2.855 3.091
#21 WT - - low 0.550 0.802
#22 BCA - - low 0.943 0.854
#23 PA - - low 1.548 1.646
#24 MEC - - low 1.880 1.752
#25 PA 1 - low 4.477 2.972
#26 PA 2 - low 1.911 2.080
#27 MEC 1 not done not done 0.366 0.828
a Tumour size 1 refers to tumours ≤ 2 cm and tumour size 2 are tumours > 2 cm. PA = pleomorphic adenoma, MC = mucinous cystadenoma, WT = Warthin
tumour, BCA = basal cell adenoma, PLGA = polymorphous low grade adenocarcinoma, ACC = adenoid cystic carcinoma, CA = cystadenocarcinoma, MEC =
mucoepidermoid carcinoma. #27 paraffin embedded tissue was small and was not used in immunohistochemistry
Figure 1 Anti-apoptotic index 1 (black bars) and 2 (white bars) in the malignant and benign salivary gland neoplasms.M o s to ft h e
samples exhibited an anti-apoptotic profile. All the pleomorphic adenoma samples exhibited more BCL-2 than CASP3 transcription. Samples #19,
#21 and #22, which showed a decreased AI-1 and 2, were p53 negative. X-axis represents the normal salivary glands pool of samples included as
reference sample in all the reactions. AI-1 = BCL-2/BAX, AI-2 = BCL-2/CASP3.
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glands (Figure 1). Altogether, the evidence points to Bcl-
2 as an important factor in the salivary gland neoplasms
pathogenesis and as a possible molecular target in sali-
vary gland tumour treatment in the future.
We did not analyze other benign/malignant lesions in
separate groups, because as they are rather unusual (eg.
adenoid cystic carcinoma, cystadenocarcinoma, muci-
nous cystadenoma) we had only a few fresh samples
included in the study. However, the expression profile
of the two mucoepidermoid samples included in the
study was unique, as one of them revealed an apoptotic
tendency (#27) and in previous immunohistochemistry
based publications, these lesions did not reveal a high
percentage of Bcl-2 positive samples [11,13].
We demonstrated an overall BCL-2 mRNA overex-
pression, as well as an increased AI-1 and AI-2 in the
salivary tumours when compared to normal salivary
glands, and in addition we found an association between
increased tumour size and high cellular proliferation
index. Although the malignant and benign group of
samples did not show difference in the AI-1/AI-2, the
malignant samples showed a statistical significant higher
cellular proliferation index. Taking these findings
together, it seems that while both, benign and malignant
tumours, tend to evade apoptosis, the malignant samples
in addition tend to have a higher cell proliferation activ-
ity, guaranteeing a growth advantage.
p53 positive samples showed higher BCL-2 transcrip-
tion levels than the negative ones, indicating an asso-
ciation of p53 immunopositivity with an increased AI-
1 and a predominantly anti-apoptotic profile. It has
been shown that p53 induces apoptosis by repressing
the transcription of the anti-apoptotic gene BCL-2 and
activating the transcription of the apoptotic BAX [20].
Such apoptotic function could be inactivated by p53
mutations. The mutated p53 is usually more stable
than the wild-type leading to higher levels of p53 and
to immunohistochemical detection of such protein.
Therefore, p53 immunoexpression in the samples ana-
lyzed may reflect loss of apoptosis induction promoted
by this protein, which may explain the increased anti-
apoptotic activity found in these tumours [21]. Accord-
ing to the last publication of the World Health Organi-
zation on Head and Neck tumours, the role of p53 in
salivary gland neoplasms is an issue of controversy [1].
In the present paper, we demonstrated an association
between malignancy and high proliferation index and
between proliferation and p53 positivity. This evidence
suggests that p53 (clone DO7) positivity may be used
as a marker in salivary tumours as it is associated not
only with higher proliferation index but also with an
anti-apoptotic profile, both contributing to tumour
growth. This apparent importance of p53 staining as a
potentially useful marker in salivary neoplasms
empowers other findings of association between higher
Figure 2 Parameters statistically associated with p53 positivity. (A) p53 immunopositivity was associated with a statistically significant
higher anti-apoptotic index 1 (p = 0.004). (B) p53 immunostaining in a sample of pleomorphic adenoma (C) high proliferation index in a sample
of polymorphous low grade adenocarcinoma. High proliferative activity was associated with p53 positivity. AI-1 = BCL-2/BAX (Original
magnification 400×).
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poor survival [17].
Conclusions
In conclusion, we demonstrate an overall anti-apoptotic
transcriptional signature in salivary gland neoplasms and
an association of it with p53 immunoexpression. In
addition, the higher proliferative activity found in the
malignant tumours suggests cell proliferation is advanta-
geous to growth of malignant salivary tumours. We
further demonstrate that tumour size is associated with
cell proliferation, but not with the transcription of apop-
totic genes.
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